Evidence map›Paper›PMID 40169528›Full record

ReviewPharmaceutical medicine2025

The Importance of Including Underserved Populations in Research.

Kayla R Mehl, Stephanie R Morain, Emily A Largent

Abstract readReview
In one paragraph

Review in Pharmaceutical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. The Experience of Stigma Within the Young Onset Dementia (YOD) Population: A Systematic Review of Qualitative Research.Health expectations : an international journal of public participation in health care and health policy · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kayla R MehlJohns Hopkins Berman Institute of Bioethics, 2129 Ashland Avenue, Baltimore, MD, 21205, USA. kmehl2@jh.edu.ORCID 0000-0003-2343-7718
Stephanie R MorainJohns Hopkins Berman Institute of Bioethics, 2129 Ashland Avenue, Baltimore, MD, 21205, USA.
Emily A LargentUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-7536-5077

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
NIA NIH HHS P30 AG072979NIA NIH HHS P30AG072979
6 · The paper itself

Abstract

This paper provides an overview of the ethical considerations surrounding the inclusion of underserved populations in later-phase clinical trials. Underserved populations, defined here as those with restricted access to or limited benefits from healthcare, often face systemic, logistical, and social barriers that limit their participation in research. This results in a lack of representation that undermines fairness in research and also hampers the development of effective inclusive healthcare practices. This paper argues that including underserved populations in research is crucial for promoting justice, increasing the generalizability of research findings, and building trust in medical institutions. It differentiates underserved populations from other populations of interest, including vulnerable, minority, and underrepresented groups. It then explores barriers to research participation and targeted solutions for four underserved populations: rural residents, racial and ethnic minorities, low-income individuals, and older adults. Strategies for improving participation include expanding trial sites to accessible locations, lowering financial and logistical barriers, broadening eligibility criteria, and fostering culturally tailored outreach and engagement. While some interventions may apply broadly across groups, effective solutions will often require intersectional and context-specific strategies tailored to each population's unique needs as well as coordinated efforts from multiple stakeholders. While these interventions alone cannot resolve healthcare inequities - as underrepresentation of underserved populations in research is just one contributing factor - their widespread implementation would represent meaningful steps toward advancing health equity.

Indexed as

Biomedical ResearchClinical Trials as TopicMedically Underserved AreaPatient SelectionVulnerable PopulationsHealth Services AccessibilityHumansMinority GroupsRural Population

Identifiers

PMID40169528
PMCPMC11980435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.